



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Southwest Region

Food and Drug Administration  
Denver District Office  
Bldg. 20-Denver Federal Center  
P.O. Box 25087  
6<sup>th</sup> Avenue & Kipling Street  
Denver, Colorado 80225-0087

Telephone: 303-236-3000

August 21, 2006

CERTIFIED MAIL  
RETURN RECEIPT REQUESTED

Mr. Bryan Flamm  
The Vitamin Trader  
211 Montano Road Northwest  
Albuquerque, New Mexico 87107

Ref. No. CL-06-HFS-810-236

Dear Mr. Flamm:

This is to advise you that the Food and Drug Administration (FDA) has reviewed your web site at the Internet address <http://www.vitamintrader.com> and has determined that the products "Amalaki" and "Gan Mao Ling" are promoted for conditions that cause the products to be drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)]. The therapeutic claims on your web site establish that the products are drugs because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The marketing of these products with these claims violates the Act.

Examples of some of the claims observed on your web site include:

**Amalaki**

"[A]nti-inflammatory, antipyretic, antiviral ... diuretic, laxative ... vulnerary"  
[Under the heading "**Traditional Uses:**"] "...allergies ... fever ... hyperglycemia ... gastritis ... toxemia ... colitis ... ulcers ... constipation ... gout ... degen. [degenerative] bone loss ... heartburn ..."

**Gan Mao Ling**

"Classic Chinese herbal formula for flu & cold symptoms"

Furthermore, your products are not generally recognized as safe and effective for the above referenced conditions and therefore, the products are also "new drugs" under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally marketed in the U.S. without prior approval from FDA as described in section 505(a) of the Act [21 U.S.C. § 355(a)]. FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective.

FDA is aware that Internet distributors may not know that the products they offer are regulated as drugs or that these drugs are not in compliance with the law. Many of these products may be legally marketed as dietary supplements if claims about diagnosis, cure, mitigation, treatment, or prevention are removed from the promotional materials and the products otherwise comply with all applicable provisions of the Act and FDA regulations.

Under the Act, as amended by the Dietary Supplement Health and Education Act, dietary supplements may be legally marketed with truthful and non-misleading claims to affect the structure or function of the body (structure/function claims), if certain requirements are met. However, claims that dietary supplements are intended to prevent, diagnose, mitigate, treat, or cure disease (disease claims), excepting health claims authorized for use by FDA, cause the products to be drugs. The intended use of a product may be established through product labels and labeling, catalogs, brochures, audio and videotapes, Internet sites, or other circumstances surrounding the distribution of the product.

FDA has published a final rule intended to clarify the distinction between structure/function claims and disease claims. This document is available on the Internet at <http://vm.cfsan.fda.gov/~lrd/fr000106.html> (codified in Title 21 of the Code of Federal Regulations, Parts 101.93(g), (21 CFR § 101.93(g)).

In addition, only products that are intended for ingestion may be lawfully marketed as dietary supplements. Topical products and products intended to enter the body directly through the skin or mucosal tissues, such as transdermal or sublingual products, are not dietary supplements. For these products, both disease and structure/function claims may cause them to be new drugs.

Certain over-the-counter drugs are not new drugs and may be legally marketed without prior approval from FDA. Additional information is available in 21 CFR § 310 and 330-358, which contain FDA's regulations on over-the-counter drugs.

This letter is not intended to be an all-inclusive review of your web site and products your firm markets. It is your responsibility to ensure that all products marketed by your firm comply with the Act and its implementing regulations.

If you need additional information or have questions concerning any products distributed through your web site, please contact FDA. You may respond in writing to Food and Drug Administration, P.O. Box 25087, Denver, Colorado, 80225-0087, Attention: William H. Sherer, Compliance Officer. Mr. Sherer may be reached at (303) 236-3051 if you have any questions about this matter.

Sincerely,

  
B. Belinda Collins  
District Director

Page 3 – Vitamin Trader, Albuquerque, NM  
August 21, 2006

bcc: DCB J&M/Legal File  
DIB/EI File FEI: 3005860961  
ALB-RP  
HFR-SW1  
GCF-1 (attorney)  
HFS-607 (Thomas)  
HFS-615 (Angeles)  
HFS-810 (Webb)  
HFS-810 (r/f)–(Barr-Thompkins/Prigmore)  
HFS-820 (Satchell)  
HFD-013 (CDER FOI)  
HFD-310 (Silvers)  
HFC-200 (Vasbinder)  
HFC-210 (Britton)  
HFC-230  
HFA-224  
WHS Chrono  
RF

Submitted to OCC: 6/6/6  
Cleared OCC:  
f/t:HFS-810:LindaWebb:DATE:CL-06-HFS-810-236  
Saved on S:\Cyber Letters\cl06hfs810236  
DDSP #: